Sanford C. Bernstein Upgrades Sanofi (NASDAQ:SNY) to “Strong-Buy”

Sanofi (NASDAQ:SNY) was upgraded by Sanford C. Bernstein to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other research analysts also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Price Performance

SNY stock opened at $54.34 on Thursday. The company has a market capitalization of $137.91 billion, a P/E ratio of 27.72, a PEG ratio of 1.21 and a beta of 0.57. The company has a fifty day moving average price of $49.24 and a 200-day moving average price of $52.27. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. As a group, equities analysts expect that Sanofi will post 3.82 EPS for the current year.

Institutional Investors Weigh In On Sanofi

Institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. increased its position in shares of Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after buying an additional 395,744 shares during the period. Natixis Advisors LLC lifted its stake in Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares in the last quarter. Raymond James & Associates boosted its holdings in Sanofi by 4.8% in the 3rd quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock valued at $162,479,000 after purchasing an additional 129,472 shares during the period. JPMorgan Chase & Co. grew its position in shares of Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, DAVENPORT & Co LLC increased its holdings in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after purchasing an additional 664,455 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.